Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Lung Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Liver Failure 1HRD Cancer 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Drug-Related Side Effects and Adverse Reactions 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Specimen Handling 40Biopsy 32Magnetic Resonance Spectroscopy 26pembrolizumab 20Nivolumab 10trastuzumab deruxtecan 9Paclitaxel 9Carboplatin 9Radiosurgery 7Irinotecan 7Gemcitabine 7X-Rays 6Pemetrexed 6Leucovorin 6Ipilimumab 6Fulvestrant 6Fluorouracil 6Cetuximab 6Bevacizumab 6palbociclib 5Taxes 5Oxaliplatin 5Cisplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Letrozole 4CTLA-4 Antigen 4ribociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × sacituzumab govitecan × 30 days × Clear all
NCT04617522 2026-06-02

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Gilead Sciences

Phase 1 Recruiting
30 enrolled

Neoplasm Metastasis, Liver Failure

NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡